Compare NOG & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOG | QURE |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | 2000 | 2013 |
| Metric | NOG | QURE |
|---|---|---|
| Price | $24.30 | $20.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $30.33 | ★ $59.52 |
| AVG Volume (30 Days) | ★ 1.8M | 1.7M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 7.44% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,475,723,000.00 | $13,107,000.00 |
| Revenue This Year | $6.03 | $44.21 |
| Revenue Next Year | $24.21 | $398.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 11.23 | N/A |
| 52 Week Low | $17.18 | $8.73 |
| 52 Week High | $31.17 | $51.72 |
| Indicator | NOG | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 35.80 |
| Support Level | $22.45 | $20.63 |
| Resistance Level | $27.53 | $26.01 |
| Average True Range (ATR) | 1.03 | 1.85 |
| MACD | -0.11 | 0.31 |
| Stochastic Oscillator | 35.58 | 2.80 |
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. The company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), the Uinta Basin, and the Appalachian Basin (Pennsylvania and Ohio).
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.